Intracystic Hemorrhage in a Patient with Pulmonary Cystic Disorder Related to Light-Chain Deposition Disease

Sarasúa, Luis Gorospe; Pacios-Blanco, Rubén-Eduardo; Arrieta, Paola; Chinea-Rodríguez, Anabelle

doi:10.1016/j.arbr.2017.03.006

Cited by 1 publication

(1 citation statement)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The clinical symptoms reported in previous studies are chest discomfort, haemoptysis, and progressive dyspnea leading to chronic respiratory failure [ 13 – 15 ]. Although no treatment is validated, chemotherapy is often prescribed to control monoclonal LC secretion in the serum [ 16 ].…”

Section: Introductionmentioning

confidence: 99%

Phenotypes and outcome of diffuse pulmonary non-amyloid light chain deposition disease

Lestelle,

Beigelman,

Rotzinger

et al. 2024

Respir Res

View full text Add to dashboard Cite

Background Light chain deposition disease (LCDD) is a very rare entity. Clinical manifestations of LCDD vary according to the organs involved. Data on pulmonary LCDD are scarce and limited to small series or case reports. This study aimed to describe the characteristics and outcome of diffuse pulmonary non-amyloid LCDD localized to the lungs. Study design and methods A multicenter retrospective cohort study was conducted. Clinical characteristics were collected, and chest CTs were centrally reviewed. The diagnosis of pulmonary non-amyloid LCDD was confirmed by immunohistochemistry. Results Thirty-one cases were identified (68% female), with a median age at diagnosis of 50 years (IQR 20). Baseline FEV1/FVC was < 0.70 in 45% of patients. Mean (± SD) FEV1 and DLCO were 86% ± 26.2 and 52% ± 23.9, respectively. CT revealed peculiar patterns of thin-walled cysts (58%) and thin-walled cystic bronchiectases (27%). Increased serum kappa light chain was found in 87% of patients. Histological analysis showed kappa light chain deposits in all patients, except one with lambda chain deposits. Median annual FEV1 decline was 127 ml (IQR 178) and median DLCO decline was 4.3% (IQR 4.3). Sixteen patients received immunomodulatory treatment or chemotherapy; serum light chain levels decreased in 9 cases (75%), without significant improvement in FEV1 (p = 0.173). Overall, 48% of patients underwent bilateral lung transplantation. Transplant-free survival at 5 and 10 years were 70% and 30%, respectively. An annual FEV1 decline greater than 127 ml/year was associated with increased risk of death or transplantation (p = 0.005). Conclusions Diffuse pulmonary LCDD is characterised by female predominance, a peculiar imaging pattern with bronchiectasis and/or cysts, progressive airway obstruction and severe DLCO impairment, and poor outcome. Lung transplantation is a treatment of choice.

show abstract

Section: Introductionmentioning

confidence: 99%